



FOR IMMEDIATE RELEASE

Tokyo, August 15, 2024

**Listing on the Japanese National Health Insurance Drug Price List and
Launch of VTAMA[®] Cream 1% in Japan**

Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced that VTAMA[®] Cream 1% (generic name: tapinarof), an aryl hydrocarbon receptor (AhR) modulating agent, has been listed on the Japanese National Health Insurance (NHI) drug price list as of today. Torii plans to launch VTAMA[®] Cream 1% in Japan on October 29, 2024.

VTAMA[®] Cream 1% is a nonsteroidal, small molecule therapeutic AhR modulating agent that suppresses the production of inflammatory cytokines and induces gene expression of skin barrier function-related and antioxidant molecules through the activation of AhR, a cytosolic ligand-dependent transcription factor. Based on this mechanism of action, VTAMA[®] Cream 1% exerts its therapeutic effect on atopic dermatitis and plaque psoriasis. In each Phase 3 comparative clinical study in patients with atopic dermatitis (≥ 12 years old) and adults with plaque psoriasis for VTAMA[®] Cream 1% conducted in Japan, the primary endpoint of efficacy demonstrated superiority to the vehicle control. Furthermore, the safety of VTAMA[®] Cream 1% has been confirmed in long-term treatment in both patient populations.

JT and Torii expect VTAMA[®] Cream 1% to be a new option for the treatment of atopic dermatitis and plaque psoriasis in Japan.

Currently, the Phase 3 clinical study in pediatric patients with atopic dermatitis (2 to 11 years old) for tapinarof cream is being conducted in Japan.

Also, VTAMA[®] (tapinarof) Cream 1%, being marketed by Dermavant Sciences, Inc. (Dermavant) in the U.S., was approved for the topical treatment of plaque psoriasis in adults in May 2022, and in April 2024, the U.S. Food and Drug Administration (FDA) accepted Dermavant's Supplemental New Drug Application (sNDA) for VTAMA[®] (tapinarof) Cream 1% for the topical treatment of atopic dermatitis in adults and children (≥ 2 years old).

ABOUT VTAMA® Cream 1%

Product Name:	VTAMA® Cream 1%
Generic Name:	Tapinarof
Indications:	Atopic dermatitis, plaque psoriasis
Dosage and Administration:	<Atopic dermatitis> For adults and pediatric patients (≥12 years old), apply an appropriate amount of cream to the affected areas once daily. < Plaque psoriasis > For adults, apply an appropriate amount of cream to the affected areas once daily.
Package:	Tubes : 15g × 1
NHI Drug Price:	¥300.80 (1% 1g)
Approval Date:	June 24, 2024
NHI Pricing Date:	August 15, 2024
Launch Date:	October 29, 2024
Manufacturing and Distributor (Import source):	Japan Tobacco Inc.
Distributor:	Torii Pharmaceutical Co., Ltd.

ABOUT Atopic Dermatitis

Atopic dermatitis is a chronic and pruritic inflammatory skin disease. It is thought to develop through exposure to various irritants or allergens for patients with a physiological abnormality of the skin (dry skin and abnormal skin barrier function).

ABOUT Plaque Psoriasis

Plaque psoriasis is a chronic, systemic, inflammatory skin disease characterized by red patches and plaques with silvery scales on the skin.

###

Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 62 factories worldwide, operating in three business segments: tobacco, pharmaceutical, and processed food. Within the tobacco business, the largest segment, products are sold in over 130 markets and its flagship brands include Winston, Camel, MEVIUS, and LD. The Group is committed to investing in Reduced-Risk Products and markets its heated tobacco products under its Ploom brand.

Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT Group's activities. Inspired by its "Fulfilling Moment, Enriching Life" purpose, the Group aims to ensure sustainable and valuable contributions to its stakeholders over the long term. In addition to our three business segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and create added-value business opportunities. For more information, visit <https://www.jt.com/>.

Contact for Japan Tobacco Inc.:

Yunosuke Miyata, Director

Investor and Media Relations Division

Japan Tobacco Inc. Tokyo: +81-3-6636-2914

E-mail: jt.media.relations@jt.com

Contact for Torii Pharmaceutical Co., Ltd.:

Corporate Planning Department

(Public Relations)

Torii Pharmaceutical Co., Ltd. Tokyo: +81-3-3231-6814

E-mail: webmaster@torii.co.jp